RRC ID 68867
Author Shindo Y, Arai W, Konno T, Kohno T, Kodera Y, Chiba H, Miyajima M, Sakuma Y, Watanabe A, Kojima T.
Title Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
Journal Histochem Cell Biol
Abstract Histone deacetylase (HDAC) inhibitors have a potential therapeutic role for non-small cell lung cancer (NSCLC). However, more preclinical studies of HDAC inhibitors in NSCLC and normal lung epithelial cells are required to evaluate their antitumor activities and mechanisms. The bicellular tight junction molecule claudin-2 (CLDN-2) is highly expressed in lung adenocarcinoma tissues and increase the proliferation of adenocarcinoma cells. Downregulation of the tricellular tight junction molecule angulin-1/LSR induces malignancy via EGF-dependent CLDN-2 and TGF-β-dependent cellular metabolism in human lung adenocarcinoma cells. In the present study, to investigate the detailed mechanisms of the antitumor activities of HDAC inhibitors in lung adenocarcinoma, human lung adenocarcinoma A549 cells and normal lung epithelial cells were treated with the HDAC inibitors Trichostatin A (TSA) and Quisinostat (JNJ-2648158) with or without TGF-β. Both HDAC inhibitors increased anguin-1/LSR, decrease CLDN-2, promoted G1 arrest and prevented the migration of A549 cells. Furthermore, TSA but not Quisinostat with or without TGF-β induced cellular metabolism indicated as the mitochondrial respiration measured using the oxygen consumption rate. In normal human lung epithelial cells, treatment with TSA and Quisinostat increased expression of LSR and CLDN-2 and decreased that of CLDN-1 with or without TGF-β in 2D culture. Quisinostat but not TSA with TGF-β increased CLDN-7 expression in 2D culture. Both HDAC inhibitors prevented disruption of the epithelial barrier measured as the permeability of FD-4 induced by TGF-β in 2.5D culture. TSA and Quisinostat have potential for use in therapy for lung adenocarcinoma via changes in the expression of angulin-1/LSR and CLDN-2.
Volume 155(6)
Pages 637-653
Published 2021-6-1
DOI 10.1007/s00418-021-01966-1
PII 10.1007/s00418-021-01966-1
PMID 33974136
MeSH Antineoplastic Agents / chemistry Antineoplastic Agents / pharmacology* Carcinoma, Non-Small-Cell Lung / drug therapy* Carcinoma, Non-Small-Cell Lung / metabolism Carcinoma, Non-Small-Cell Lung / pathology Cell Movement / drug effects Cell Proliferation / drug effects Cells, Cultured Drug Screening Assays, Antitumor Histone Deacetylase Inhibitors / chemistry Histone Deacetylase Inhibitors / pharmacology* Humans Hydroxamic Acids / chemistry Hydroxamic Acids / pharmacology* Lung Neoplasms / drug therapy* Lung Neoplasms / metabolism Lung Neoplasms / pathology Tight Junction Proteins / antagonists & inhibitors* Tight Junction Proteins / metabolism
IF 3.418
Human and Animal Cells A549(RCB0098)